Back to today’s briefing

Story perspectives

Dublin Startup Aerska Secures €17M for RNAi Medicines

10/3/2025

35 5

Summary

Story summary

Aerska, a Dublin-based biotechnology startup, has raised €17 million in Seed financing to develop RNA interference (RNAi) medicines for neurological diseases.
Co-led by Age1, Backed VC, and Speedinvest, reflecting investor confidence in Aerska's approach.
The company targets the blood-brain barrier with brain shuttles for gene silencing, initially focusing on genetic forms of Alzheimer’s and Parkinson’s.

1 of 1

Story summary

Aerska, a Dublin-based biotechnology startup, has raised €17 million in Seed financing to develop RNA interference (RNAi) medicines for neurological diseases.
Co-led by Age1, Backed VC, and Speedinvest, reflecting investor confidence in Aerska's approach.
The company targets the blood-brain barrier with brain shuttles for gene silencing, initially focusing on genetic forms of Alzheimer’s and Parkinson’s.